Federal Register Notice: FDA will hold a public hearing 2/25 to obtain input on the agency’s regulation of drugs for treating and/or managing amyotrophic lateral sclerosis (ALS). The input will help inform the work of FDA offices that review applications for drugs for the treatment of ALS. The hearing will be held from about 9 a.m. to 5 p.m. at the FDA White Oak Campus, 10903 New Hampshire Ave., Bldg. 31, Rm. 1503B, Silver Spring, MD. Contact David Banks, (301) 796-8459. To view this notice, click here.